Clorox stock steadies above $100 as fiscal 2027 outlook supports the rebound
Published on 08/22/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Clorox Co. (US1890541097) stock is trading just above $100 as investors weigh a mixed fiscal fourth quarter, a detailed fiscal 2027 outlook, and renewed institutional interest after the most recent results for the quarter ended June 30, 2026 were released on August 21, 2026.
The company reported adjusted earnings of $1.66 per share in that fiscal fourth quarter on net sales of $1.95 billion, modestly ahead of consensus estimates for $1.64 in earnings and $1.91 billion in revenue in the same period.
Despite the beats, sales in the quarter declined 2 percent year over year and gross margin pressures highlighted the challenge of absorbing higher costs and ERP comparisons even as management looks ahead to stronger growth in fiscal 2027.
As of the August 21, 2026 session, Clorox stock opened at $106, giving the company a quoted market value of $12.82 billion and leaving the shares trading several dollars above the average analyst target of $102.40, according to data compiled from recent coverage.
Recent commentary indicates that the shares have gained 13.1 percent over the past month as the market responds to the new outlook and to improved sentiment around the company’s margin and supply chain plans following the latest quarter.
Fourth quarter 2026 results and margin pressure
For the fiscal fourth quarter ended June 30, 2026, Clorox generated net sales of $1.95 billion, outperforming the consensus forecast of $1.91 billion by $40 million and demonstrating that demand held up better than analysts anticipated even as some categories softened.
On the bottom line, adjusted earnings of $1.66 per share exceeded the $1.64 consensus by $0.02, a small but important beat that helped support the recent share price recovery as investors reassessed the earnings power heading into the new fiscal year.
Year over year, however, the comparison remains challenging: fiscal fourth quarter sales fell 2 percent, and the same quarter a year earlier delivered $2.87 in earnings per share, underscoring how sharply profit per share has reset from prior levels.
The Health and Wellness segment was a notable bright spot, with segment sales rising 16 percent to $860 million in the quarter, driven in large part by the full-period consolidation of the GOJO business that Clorox acquired, which added 28 percentage points to growth in that segment alone.
Across the company, GOJO contributed around 10 percentage points to reported sales growth in the quarter, helping offset a 13 percent decline in organic sales that largely reflected tough comparisons related to earlier ERP shipment timing and a normalization in some categories.
Despite the support from acquisitions, profitability was under pressure: fiscal 2026 gross margin declined 290 basis points to 42.3 percent, and fourth quarter gross margin dropped 520 basis points to 41.3 percent, with about 150 basis points of pressure each from ERP shipment comparisons and GOJO inventory step-up costs alongside higher commodity, manufacturing, and logistics expenses.
For investors, these margin figures make clear that the central task for management in fiscal 2027 is to convert the expected top-line acceleration into more durable profit expansion while absorbing the remaining integration and systems costs.
Fiscal 2027 guidance and analyst view
Looking ahead, Clorox has issued fiscal 2027 guidance that calls for total net sales to increase 13 to 14 percent, a notable acceleration from the slight decline in fiscal 2026 and a sign of confidence in both the core portfolio and the GOJO contribution.
Within that outlook, management expects the GOJO acquisition to contribute roughly 9.5 percentage points to overall sales growth in fiscal 2027, implying that the remainder of the portfolio still needs to deliver mid-single-digit growth to achieve the full-year target.
On earnings, the company projects adjusted earnings for fiscal 2027 in a range of $5.70 to $6.00 per share, which represents growth of 3 to 8 percent compared with the latest full-year baseline and suggests that margin recovery will be gradual rather than dramatic.
Sell-side consensus aligns closely with that guidance, with analysts currently forecasting 5.8 in earnings per share for the current fiscal year, placing their midpoint slightly below the top of management’s range but comfortably within it.
The quantified comparison between guidance and consensus matters: the midpoint of the company’s projected earnings range is $5.85 per share, only $0.05 above the consensus 5.8 figure, pointing to limited room for disappointment but also limited implied upside if execution simply matches expectations.
Recent data shows that the average rating on Clorox stock stands at Reduce and the average twelve-month price target is $102.40, which is $3.60 below the recent $106 opening price and signals that many analysts still view the shares as fully valued after the latest rebound.
For investors, that imbalance between the current price level and the consensus target is an important valuation marker: if the shares hold above $100 while the average target stays near $102, the market is effectively demanding either faster growth or a more substantial margin recovery than current models assume.
Stock performance, institutional interest and risk markers
Price action around the August 21, 2026 session highlights renewed interest in Clorox stock: with the shares opening at $106 and sitting above the $100 threshold, the recent 13.1 percent one-month gain suggests that the market has reassessed the company’s post-disruption earnings path positively.
Based on the quoted market cap of $12.82 billion and the guided earnings range, the shares trade at approximately 18.3 to 18.9 times projected fiscal 2027 earnings, using the $5.70 to $6.00 per-share guidance range, a valuation that many observers see as demanding for a business still working through margin headwinds.
The recent institutional activity underscores that not all large investors share the cautious stance: new holdings have been reported by multiple professional asset managers over the latest period, signaling that some long-term capital is willing to commit at the current valuation.
One instant-alert filing described a large asset manager acquiring more than 10 million shares of Clorox, while another reported a specialist fund buying 52,602 shares, showing that accumulation has taken place at price levels fairly close to the current $106 trading zone.
These purchases, alongside the broader one-month price gain, indicate that the latest quarter and fiscal 2027 guidance have been sufficient to convince at least part of the institutional community that the company can navigate its ERP-related shipment comparisons and cost inflation without a deeper earnings reset.
At the same time, margin compression remains a central risk marker: with fiscal 2026 gross margin down 290 basis points and fourth quarter margin down 520 basis points, the guidance for only 3 to 8 percent earnings growth leaves limited buffer if costs stay elevated or if the GOJO contribution does not fully materialize as expected.
For investors tracking valuation against fundamentals, the comparison between the current $12.82 billion market value and the guided earnings range suggests that Clorox is priced for a steady, not spectacular, recovery, making execution on supply chain, pricing, and cost control key to sustaining the more than 13 percent recent share price advance.
Cleaning and disinfecting products underpin the story
Behind the numbers, Clorox’s core portfolio of cleaning and disinfecting products remains central to its long-term investment case, as these brands anchor consumer loyalty and drive repeat purchases in both households and professional settings.
The company’s flagship Clorox-branded bleach and disinfecting wipes continue to serve as essential items in many homes, providing surface disinfection and stain removal that support hygiene and cleanliness, particularly in kitchens and bathrooms.
In addition to bleach, Clorox offers a range of cleaners, sprays, and wipes designed for different surfaces and uses, from bathroom cleaners that tackle soap scum and mildew to multipurpose sprays that handle everyday spills and messes.
Professional customers, including schools, hospitals, and businesses, also rely on Clorox-branded disinfectants and cleaning systems to maintain hygiene standards, a demand base that became more visible during health crises and remains important as institutions seek reliable disinfection solutions.
The GOJO acquisition, which brought the Purell brand into Clorox’s broader portfolio, adds further exposure to hand hygiene products, strengthening the company’s positioning in both consumer and professional sanitizing categories and supporting the expected 9.5 percentage-point contribution to fiscal 2027 sales growth.
While daily share price moves respond to earnings beats and guidance tweaks, this combination of surface cleaning, disinfecting, and hand hygiene products provides the operational backbone that generates the $1.95 billion quarterly sales, and it is the durability of this demand that underpins management’s confidence in a 13 to 14 percent net sales increase in fiscal 2027.
Shares trade above $100 with valuation tied to guidance
Clorox Co. shares are listed on the New York Stock Exchange under the ticker CLX, and the most recent quoted data show the stock opening at $106 on August 21, 2026 in U.S. trading, with that level serving as a reference point for the current valuation discussion.
At that $106 opening price and a reported market value of $12.82 billion as of August 21, 2026, investors can translate the company’s fiscal 2027 earnings guidance of $5.70 to $6.00 per share into a forward price-to-earnings multiple in the high teens, a range that reflects both the defensive nature of the cleaning products portfolio and the risk that margin recovery may proceed slowly.
For market participants considering Clorox stock today, the key tension is clear: the shares have already climbed 13.1 percent in the past month and stand several dollars above the average $102.40 analyst target, so further gains will likely depend on the company delivering on its 13 to 14 percent net sales growth target and demonstrating that gross margins can rebuild from the 42.3 percent full-year and 41.3 percent fourth quarter levels reported for fiscal 2026.
